Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

Inclusion Criteria:

* Subjects are between 50 and 75 years of age;
* Have not had known or suspected infection with SARS-CoV-2 at any time;
* Subjects must fall into one of the following subsets of cancer patients:

  * Localized prostate cancer on radiotherapy or have completed radiotherapy in the last three months
  * Prostate cancer on androgen-deprivation therapy for biochemical recurrence
  * Colon cancer on adjuvant chemotherapy for stage III disease
  * CLL on a BTK inhibitor as a first-line single agent for at least 3 months
  * Melanoma patients on adjuvant immunotherapy with PD-1 checkpoint inhibitors for at least 3 months
* Have received both doses of SARS-CoV-2 mRNA-1273 vaccine with proof of vaccination or are scheduled to do so;
* Have at least a one-year life expectancy;
* Prior radiation therapy is allowed, as long as it was completed more than 6 months prior to vaccination

Exclusion Criteria:

* Subjects have a known hypersensitivity to a vaccine component;
* Have had known or suspected infection with SARS-CoV-2 at any time;
* Are organ transplant recipient on immunosuppression;
* Had received or are scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post second dose;
* Had received or are scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to Dose 1 through 7 days post second dose;
* Received high-dose corticosteroids at any time after receiving the vaccine;
* Are unable to give informed consent;
* Are receiving treatment for CLL with another agent (such as rituximab) in addition to a BTK inhibitor